Portugal
Portuguese company wants to find an antibody against Ebola by the end of the year
Publication: PÚBLICO
Author: publico@publico.pt
Source published: 27/09/2026, 06:07:00 UTC
Briefing created: 27/09/2026, 07:09:40 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/09/2026, 07:05:25 UTC.
Briefings
A Portuguese pharmaceutical company Lxbio is actively seeking a potential Ebola vaccine candidate to combat the outbreak in the Democratic Republic of Congo, with the goal of securing approval by the end of 2026.
Key points
- Lxbio, a Portuguese pharmaceutical firm, is conducting research to develop a vaccine against Ebola in the Democratic Republic of Congo.
- The company aims to obtain regulatory approval for the vaccine by December 2026 to address the ongoing outbreak.
Context and limitations
The provided evidence is limited to the company's stated objective and the expected timeframe for approval, without details on the research methodology, current clinical trial status, or specific candidate characteristics.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/09/2026, 07:09:40 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeifxym5avng2setdq5e3dx5ujhpsn3v3r7kfa3xem756bd5hbstoc4